Estudio abierto, multicéntrico, Fase 2 de CNTO 888 (anticuerpo monoclonal anti-CCL2) como agente único para el tratamiento de sujetos con cáncer de ovario recurrente.
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2012
At a glance
- Drugs Carlumab (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 28 Apr 2012 Additional location [United Kingdom] identified as reported by as reported by European Clinical Trials Database.
- 28 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 14 Jun 2011 New trial record